Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
NCT04919642
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Cholangiocarcinoma
FGFR2 Fusion
FGFR2 Gene Mutation
FGFR1 Alteration
FGFR3 Alteration
Interventions
DRUG:
TT-00420
Sponsor
TransThera Sciences (Nanjing), Inc.